For research use only
| Cat No. | ABC-X0142C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Host Cell | A549 |
| Source Organ | Lung |
| Disease | Lung Cancer |
| Storage | Liquid Nitrogen |
The Xpress™ CD228 A549 overexpression cell line provides a powerful tool for lung cancer research, helping you gain insights into tumor cell adhesion.
Xpress™ Human CD228 over-expressing cell line (A549) is a genetically engineered model derived from selected human lung adenocarcinoma A549 parental cell line. CD228 A549 overexpression cell line is generated by stable integration of exogenous human CD228 (also known as MUC18 or MCAM) into A549 host cells using our optimized transduction of lentiviral vectors. Overexpression clone is validated at gene level by qRT-PCR.
Target
The CD228 gene encodes a cell surface glycoprotein belonging to the immunoglobulin superfamily, involved in cell adhesion, signal transduction, and tumor progression. CD228 expression is elevated in various cancers, including melanoma, prostate cancer, and non-small cell lung cancer (NSCLC), where it promotes cell migration, invasion, and angiogenesis. It activates pathways such as PI3K/AKT and MAPK, contributing to metastasis and therapy resistance. The protein localizes predominantly to the plasma membrane and is a potential target for antibody-based therapies in oncology.
| Species | Human |
| Cat.No | ABC-X0142C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Lung |
| Disease | Lung Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | A549 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The CD228 A549 Overexpression Cell Line serves as a powerful tool to investigate CD228-mediated oncogenic pathways and evaluate therapeutic strategies in lung cancer. This model supports mechanistic studies of tumor cell adhesion, migration, and immune evasion in the tumor microenvironment. It is suitable for high-throughput screening of CD228-targeted treatments, including monoclonal antibodies and immune checkpoint modulators.